Incomplete antibody evolution and seroreversion after treatment of primary HIV type 1 infection: What is the clinical significance?

Clinical Infectious Diseases

Volumn 40, Issue 6, 2005, Pages 874-875

  Connick, Elizabeth ^a  

^a UNIVERSITY OF COLORADO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER;

ANTIBODY PRODUCTION; ANTIBODY RESPONSE; ANTIBODY TITER; BLOOD; CELL SECRETION; CLINICAL OBSERVATION; DISEASE ASSOCIATION; DISEASE COURSE; DRUG EFFECT; GENE DELETION; GENETIC ANALYSIS; HELPER CELL; HEPATITIS B; HEPATITIS C; HEPATITIS C VIRUS; HETEROZYGOSITY; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HOST; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMORAL IMMUNITY; HYPOTHESIS; IMMUNE DEFICIENCY; IMMUNE RESPONSE; NONHUMAN; NOTE; PATHOGENESIS; PATIENT; PLASMA CELL; PRIORITY JOURNAL; SEROCONVERSION; SEROREVERSION; STIMULATION; TETANUS; VIRUS LOAD; VIRUS REPLICATION;

ANTI-HIV AGENTS; DRUG ADMINISTRATION SCHEDULE; HIV ANTIBODIES; HIV INFECTIONS; HUMANS;

EID: 14944349107     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/428131     Document Type: Note

References (19)

1. Kassutto M, Johnston MN, Rosenberg ES. Incomplete HIV-1 antibody evolution and seroreversion in acutely infected individuals treated with early antiretroviral therapy. Clin Infect Dis 2005; 40:868-73 (in this issue).
2. Lepage P, Van de Perre P, Simonon A, Msellati P, Hitimana DG, Dabis F. Transient seroreversion in children born to human immunodeficiency virus 1-infected mothers. Pediatr Infect Dis J 1992; 11:892-4.
3. Chantry CJ, Cooper ER, Pelton SI, Zorilla C, Hillyer GV, Diaz C. Seroreversion in human immunodeficiency virus-exposed but uninfected infants. Pediatr Infect Dis J 1995; 14:382-7.
4. Gutierrez M, Soriano V, Bravo R, Vallejo A, Gonzalez-Lahoz J. Seroreversion in patients with end-stage HIV infection. Vox Sang 1994; 67:238-9.
5. Roy MJ, Damato JJ, Burke DS. Absence of true seroreversion of HIV-1 antibody in seroreactive individuals. JAMA 1993; 269:2876-9.
6. Lu Y, Pauza CD, Lu X, Montefiori DC, Miller CJ. Rhesus macaques that become systemically infected with pathogenic SHIV 89.6-PD after intravenous, rectal, or vaginal inoculation and fail to make an antiviral antibody response rapidly develop AIDS. J Acquir Immune Defic Syndr Hum Retrovirol 1998; 19:6-18.
7. Soriano V, Dronda F, Gonzalez-Lopez A, et al. HIV-1 causing AIDS and death in a seronegative individual. Vox Sang 1994; 67:410-1.
8. Martin-Rico P, Pedersen C, Skinhoj P, Nielsen C, Lindhardt BO. Rapid development of AIDS in an HIV-1-antibody-negative homosexual man. AIDS 1995; 9:95-6.
9. Michael NL, Brown AE, Voigt RF, et al. Rapid disease progression without seroconversion following primary human immunodeficiency virus type 1 infection - evidence for highly susceptible human hosts. J Infect Dis 1997; 175:1352-9.
10. Morris L, Binley JM, Clas BA, et al. HIV-1 antigen-specific and -nonspecific B cell responses are sensitive to combination antiretroviral therapy. J Exp Med 1998; 188:233-45.
11. Kim JH, Mascola JR, Ratto-Kim S, et al. Selective increases in HIV-specific neutralizing antibody and partial reconstitution of cellular immune responses during prolonged, successful drug therapy of HIV infection. AIDS Res Hum Retroviruses 2001; 17:1021-34.
12. Dorn J, Masciotra S, Yang C, et al. Analysis of genetic variability within the immunodominant epitopes of envelope gp41 from human immunodeficiency virus type 1 (HIV-1) group M and its impact on HIV-1 antibody detection. J Clin Microbiol 2000; 38:773-80.
13. O'Connell RJ, Merritt TM, Malia JA, et al. Performance of the OraQuick rapid antibody test for diagnosis of human immunodeficiency virus type 1 infection in patients with various levels of exposure to highly active antiretroviral therapy. J Clin Microbiol 2003; 41:2153-5.
14. Jurriaans S, Sankatsing SU, Prins JM, et al. HIV-1 seroreversion in an HIV-1-seropositive patient treated during acute infection with highly active antiretroviral therapy and mycophenolate mofetil. AIDS 2004; 18:1607-8.
15. Siliciano JD, Siliciano RF. A long-term latent reservoir for HIV-1: discovery and clinical implications. J Antimicrob Chemother 2004; 54:6-9.
16. Fitzgerald W, Sylwester AW, Grivel JC, Lifson JD, Margolis LB. Noninfectious X4 but not R5 human immunodeficiency virus type 1 virions inhibit humoral immune responses in human lymphoid tissue ex vivo. J Virol 2004; 78:7061-8.
17. Marinho RT, Pinto RM, Santos ML, de Moura MC. Lymphocyte T helper-specific reactivity in sustained responders to interferon and ribavirin with negativation (seroreversion) of anti-hepatitis C virus. Liver Int 2004; 24:413-8.
18. Manz RA, Hauser AE, Hiepe F, Radbruch A. Maintenance of serum antibody levels. Annu Rev Immunol 2005; 23 367-86.
19. Kilby JM, Goepfert PA, Miller AP, et al. Recurrence of the acute HIV syndrome after interruption of antiretroviral therapy in a patient with chronic HIV infection: a case report. Ann Intern Med 2000; 133:435-8.